Jiangsu Hansoh Pharma is planning a $3 billion Hong Kong IPO, which would be a record for an initial pharma offering in Hong Kong; Simcere Pharma of Nanjing plans to re-list in a $1 billion IPO, also in Hong Kong; Shanghai’s Zai Lab raised more than $100 million in a Series B financing; BioAtla will make $70 million in payments to Beijing Sinobioway as part of their collaboration; Dalian Wanda Group announced a $2.3 billion investment in three China hospitals; ASLAN Pharma of Singapore added oncology indications to a drug it had previously in-licensed from Admirall; Taipei Medical University licensed Asian rights to a Lixte Biotech cancer drug candidate; Johnson & Johnson acquired ex-China rights to immune adjuvants from a Sino Biopharma subsidiary; ChemPartner, a China-US CRO, added peptide chemistry to its services and invested in Circle Pharma, a peptide company; Nuance Biotech of Shanghai optioned two cancer treatments from Oxford’s Celleron Therapeutics; CANbridge Life Sciences, a Beijing biopharma, will make a milestone payment to Apogenix after completing a brain cancer biomarker study; Sagent Pharma of the US will sell its China subsidiary at a loss of up to $50 million; Suzhou Connect Biopharma reported positive data from a Phase Ib trial of its immune system modulator; Yisheng Biopharma of Beijing said its PIKA-adjuvant rabies vaccine was effective in an early trial; Sinovac received CFDA approval for its hand-foot-mouth disease vaccine; and WuXi AppTec announced a $120 million integrated biologics facility at the company’s Shanghai headquarters.
